Get the Stockscreener App
10.49
2.87%
-0.31
Rapt Therapeutics Inc stock is traded at $10.49, with a volume of 31,794.
It is down -2.87% in the last 24 hours and up +43.11% over the past month.
RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.
See More
Previous Close:
$10.80
Open:
$10.57
24h Volume:
31,794
Relative Volume:
0.29
Market Cap:
$178.59M
Revenue:
$3.25M
Net Income/Loss:
$-116.80M
P/E Ratio:
-3.4393
EPS:
-3.05
Net Cash Flow:
$-98.17M
1W Performance:
-21.19%
1M Performance:
+43.11%
6M Performance:
+15.02%
1Y Performance:
-57.97%
1-Day Range:
$10.10
$10.98
1-Week Range:
$10.10
$13.50
52-Week Range:
$5.6652
$26.56
Rapt Therapeutics Inc Stock (RAPT) Company Profile
Name
Rapt Therapeutics Inc
Sector
Industry
Phone
(650) 489-9000
Address
561 ECCLES AVENUE, SOUTH SAN FRANCISCO, CA
Compare RAPT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RAPT
Rapt Therapeutics Inc
|
10.49 | 178.59M | 3.25M | -116.80M | -98.17M | -3.05 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Rapt Therapeutics Inc Stock (RAPT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-30-25 | Upgrade | JP Morgan | Underweight → Neutral |
| May-22-25 | Resumed | H.C. Wainwright | Buy |
| Dec-26-24 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Nov-13-24 | Downgrade | Stifel | Buy → Hold |
| Nov-11-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Nov-11-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| May-14-24 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| May-10-24 | Downgrade | Barclays | Overweight → Equal Weight |
| May-10-24 | Downgrade | Guggenheim | Buy → Neutral |
| Feb-22-24 | Downgrade | UBS | Buy → Neutral |
| Feb-21-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Feb-21-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-21-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Feb-20-24 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Feb-16-24 | Initiated | Evercore ISI | Outperform |
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Sep-14-23 | Initiated | Berenberg | Buy |
| Aug-09-23 | Initiated | Stifel | Buy |
| Jun-15-23 | Initiated | Barclays | Overweight |
| Jan-04-23 | Initiated | Guggenheim | Buy |
| Dec-01-22 | Initiated | Goldman | Buy |
| Sep-21-22 | Initiated | CapitalOne | Overweight |
| May-24-22 | Resumed | Cantor Fitzgerald | Overweight |
| Dec-09-21 | Initiated | JP Morgan | Overweight |
| Aug-12-21 | Initiated | SVB Leerink | Outperform |
| Jun-21-21 | Initiated | Piper Sandler | Overweight |
| Jun-01-20 | Initiated | H.C. Wainwright | Buy |
| May-19-20 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-13-20 | Initiated | ROTH Capital | Buy |
| Nov-25-19 | Initiated | BMO Capital Markets | Outperform |
| Nov-25-19 | Initiated | UBS | Buy |
| Nov-25-19 | Initiated | Wells Fargo | Outperform |
View All
Rapt Therapeutics Inc Stock (RAPT) Latest News
Why RAPT Therapeutics Inc. stock attracts strong analyst attentionShort-Term Profit Alert With Entry Forecast - Newser
Using Ichimoku Cloud for RAPT Therapeutics Inc. technicalsFree Swing Setup With Technical Confirmation - Newser
Wall Street Analysts Believe Rapt Therapeutics (RAPT) Could Rally 122.22%: Here's is How to Trade - Yahoo Finance
Rapt Therapeutics (NASDAQ:RAPT) Raised to Neutral at JPMorgan Chase & Co. - Defense World
Volatility clustering patterns for RAPT Therapeutics Inc.Free Low Risk High Return Opportunities - Newser
Has RAPT Therapeutics Inc. formed a bullish divergenceSwing Reversal Forecast Based on Patterns - Newser
How to forecast RAPT Therapeutics Inc. trends using time seriesFree Investment Plan With Growth Optimization - Newser
What machine learning models say about RAPT Therapeutics Inc.Free Technical Entry Strategy for Beginners - Newser
Applying sector rotation models to RAPT Therapeutics Inc.Top Stock Picks with Forecast Accuracy - Newser
Using data filters to optimize entry into RAPT Therapeutics Inc.Growth Summary Based on Market Positioning - Newser
JPMorgan Upgrades Rapt Therapeutics (RAPT) to Neutral with New Price Target of $14 - AInvest
Rapt Therapeutics Upgraded to Neutral by JPMorgan, Price Target Set at $14 - AInvest
Custom watchlist performance reports with RAPT Therapeutics Inc.Pattern Breakout Prediction for Short Term - Newser
RAPT Therapeutics upgraded by JPMorgan to Neutral with $14 PT. - AInvest
JPMorgan upgrades Rapt Therapeutics stock rating to Neutral from Underweight - Investing.com
News impact scoring models applied to RAPT Therapeutics Inc.Sector-Wise Stock Strength Trend Analysis - Newser
RAPT Therapeutics Inc. Building a Base Near SupportTriple Digit Growth Focused Trade Plan Reviewed - metal.it
How does RAPT Therapeutics Inc. compare to its industry peersUnlock exclusive trading strategies for gains - jammulinksnews.com
What catalysts could drive RAPT Therapeutics Inc. stock higher in 2025Financial News Watchlist For 2025 - jammulinksnews.com
Building trade automation scripts for RAPT Therapeutics Inc.Asset Allocation Summary With Future Outlook - Newser
Custom watchlist performance reports with RAPT Therapeutics Inc. Stable Profit Zone and Loss Control Analysis - Newser
Wall Street Zen Upgrades Rapt Therapeutics (NASDAQ:RAPT) to Hold - Defense World
What is the risk reward ratio of investing in RAPT Therapeutics Inc. stockAchieve breakthrough investment performance - jammulinksnews.com
Is RAPT Therapeutics Inc. stock overvalued or undervaluedSuperior portfolio returns - jammulinksnews.com
Should I hold or sell RAPT Therapeutics Inc. stock in 2025Get ahead with breakthrough trading ideas - jammulinksnews.com
Published on: 2025-07-27 20:48:32 - jammulinksnews.com
Lifesci Capital Weighs in on RAPT Q2 Earnings - Defense World
Rapt Therapeutics (NASDAQ:RAPT) Upgraded at Lifesci Capital - Defense World
Is RAPT Therapeutics Inc. stock overhyped or has real potentialHigh-margin investment plays - jammulinksnews.com
Is RAPT Therapeutics Inc. a good long term investmentMassive profits - Autocar Professional
What analysts say about RAPT Therapeutics Inc. stockRapid wealth accumulation - PrintWeekIndia
RAPT Therapeutics Inc. Stock Analysis and ForecastConsistent high-performance stocks - PrintWeekIndia
Can RAPT Therapeutics Inc. stock recover from recent declineExceptional earning trajectories - jammulinksnews.com
What drives RAPT Therapeutics Inc. stock priceFree Technical Analysis Support - PrintWeekIndia
Rapt Therapeutics (NASDAQ:RAPT) Receives Consensus Rating of “Hold” from Analysts - Defense World
Rapt Therapeutics Inc Stock (RAPT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):